Navigation Links
New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
Date:11/21/2008

nical experience have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly, and it may be useful to assess renal function in these patients prior to initiating dosing and periodically thereafter.

Additional Information about JANUVIA

In controlled clinical studies as both monotherapy and combination therapy with metformin or pioglitazone, the overall incidences of adverse reactions, hypoglycemia, and discontinuation of therapy due to clinical adverse reactions with JANUVIA were similar to placebo. In these clinical studies, the most common adverse reactions reported with JANUVIA (e 5 percent and higher than placebo) were stuffy or runny nose and sore throat, upper respiratory infection and headache. In clinical trials in combination with a sulfonylurea (glimepiride), with or without metformin, JANUVIA demonstrated an overall incidence of adverse reactions higher than that seen with placebo, in part related to a higher incidence of hypoglycemia.

In a pre-specified pooled analysis of two monotherapy studies, an add-on to metformin study, and an add-on to pioglitazone study, the overall incidence of adverse reactions of hypoglycemia in patients treated with JANUVIA 100 mg was similar to placebo (1.2 percent vs. 0.9 percent). Adverse reactions of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. In an additional, 24-week, placebo-controlled factorial study of initial therapy with sitagliptin in combination with metformin, the incidence of hypoglycemia was 0.6 percent in patients given placebo, 0.6 percent in patients given sitagliptin alone, 0.8 percent in patients given metformin alone and 1.6 perce
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
2. Landmark study defines benefits of early HIV testing and treatment for infected infants
3. Study identifies causes of bone loss in breast cancer survivors
4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
5. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
6. Rutgers researchers study cites media violence as critical risk factor for aggression
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
9. New Study Finds CO2 Ablative Fractional Resurfacing Safe And Effective For Deep Acne Scarring
10. Study investigates Gore-tex-type device to stop strokes and mini-strokes
11. The smart way to study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... Consumer demand for healthy lifestyle drives new store openings, ... new year means,a new resolution or two. For GNC, ... the supplement industry is expected to rise steadily,through 2012, ... time for GNC to once again expand its store ...
... Phase 2 Clinical Trials,Dow AgroSciences CEO Discusses Future Opportunities ... Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) announced that the ... and preview objectives for 2008 during its,annual Investor and ... Jerome Peribere, President and CEO of Dow AgroSciences will ...
... a division of Wyeth (NYSE: WYE ), ... leading scientific and pharmaceutical,achievements at the third annual ... 4. Wyeth received honors for Best Overall Pipeline, ... by Scrip World Pharmaceutical News,a leading source of ...
... -- Apart from a more complicated medical case, ... time with their patients" Researchers at UC Davis ... that affect the length of a patients medical ... the doctors visit. , In a new ...
... Drug has significant risks, and its benefits are still debated, ... U.S. Food and Drug Administration advisory panel recommended Wednesday that ... women with advanced breast cancer. , In a close vote, ... the growth of tumors did not outweigh the increased risk ...
... two Phase III clinical trials support that Asacol, an ... agents known as 5-aminosalicylic acids (5-ASAs), is an effective ... ulcerative colitis (UC), including isolated proctitis. The results ... dosed at 2.4 g/day for six weeks, experienced significant ...
Cached Medicine News:Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 3Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 4Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 5Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 6Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 7Health News:Wyeth Receives Honors at the 2007 Scrip Awards 2Health News:Wyeth Receives Honors at the 2007 Scrip Awards 3Health News:Wyeth Receives Honors at the 2007 Scrip Awards 4Health News:Wyeth Receives Honors at the 2007 Scrip Awards 5Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:Asacol treats UC symptoms of isolated proctitis 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 21 More than one in three diabetes ... prescribed, stating that they have done so on average three ... estimate that in reality this number could be as high ... and Physicians in Insulin Therapy (GAPP™) survey, released today by ...
... WESTLAKE VILLAGE, Calif., Sept. 21 As consumer ... on overall pharmacy customer satisfaction has increased considerably ... Associates 2010 U.S. National Pharmacy Study(SM) released today. ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) The ...
Cached Medicine Technology:New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 2New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 2J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 4J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 5
... (PNET) is the foundation and supporting ... systems. This extremely versatile software supports ... for all the GI diagnostic testing ... and catheter-based ambulatory pH testing, esophageal ...
Symbia T, a TruePoint SPECTCT system, combines a dual-detector variable angle gamma camera with a CT scanner optimized for rapid, accurate attenuation correction of the nuclear data....
... STAT analyzer and data management system ... meet the traditional needs of data management ... for the management of STAT analyzer systems., ... simple connectivity solution for both STAT analyzers ...
... Enterprise is a comprehensive IT solution ... from admission to follow-up. This scalable ... and diagnostic tools from syngo Dynamics ... single, longitudinal clinical repository that becomes ...
Medicine Products: